Growth Potential Assets


Revenue Generative Assets

Altan is a specialty pharmaceutical company developing, manufacturing and commercialising injectable drugs for the hospital and other provider segments. Altan is focused on building its pipeline of injectable drugs and expanding its commercial presence to new markets. More recently Altan is specifically targeting the US intravenous paracetamol market, having had a New Drug Application filing accepted for review by the US FDA.

> go to website

Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its unique non-mercury, full-spectrum disinfection LightStrikeTM Germ-ZappingTM robots. Xenex aims to become the new standard of care for disinfection in healthcare facilities worldwide, eliminating harmful bacteria, viruses and fungi which can cause healthcare associated infections in patients and staff.

> go to website

Early-stage Assets

Artizan is an early-stage biotechnology company focused on developing a platform to eliminate disease-causing bacteria in the gut microbiota. Artizan's initial focus is on inflammatory bowel disease, specifically Crohn's Disease and Ulcerative Colitis.

> go to website

Wren is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden) focused on drug discovery and development for protein misfolding diseases including Alzheimer's and Parkinson's. Wren’s proprietary approach is based on more than a decade of research focused on the chemical kinetics of the protein misfolding process. Wren is developing a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases.

> go to website

Public Asset

Novan is a clinical-stage biotechnology company focused on leveraging nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-medicated diseases. The two key components of Novan's nitric oxide platform are its proprietary NitricilTM technology, which drives the creation of new chemical entities, and its topical formulation science, both of which are used to modulate product candidate for specific indications.

> go to website